World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes

British Journal of Haematology

Volumn 137, Issue 3, 2007, Pages 193-205

  Bernasconi, Paolo ^a,b   Klersy, Catherine ^a   Boni, Marina ^b   Cavigliano, Paola M ^b   Calatroni, Silvia ^b   Giardini, Ilaria ^b   Rocca, Barbara ^b   Zappatore, Rita ^b   Caresana, Marilena ^b   Dambruoso, Irene ^b   Lazzarino, Mario ^b   Bernasconi, Carlo ^b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Cytogenetics; Myelodysplastic syndromes; Prognostic factors

Indexed keywords

ADULT; AGED; ARTICLE; BLAST CELL; CHROMOSOME 20Q; CHROMOSOME 3; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHROMOSOME MARKER; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE CLASSIFICATION; DYSPLASIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; SURVIVAL RATE; TRISOMY 8; WORLD HEALTH ORGANIZATION;

ADULT; AGED; CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 12; CHROMOSOMES, HUMAN, PAIR 20; CHROMOSOMES, HUMAN, PAIR 3; CHROMOSOMES, HUMAN, PAIR 7; CHROMOSOMES, HUMAN, PAIR 8; CYTOGENETIC ANALYSIS; DISEASE PROGRESSION; FEMALE; HUMANS; KARYOTYPING; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; TRISOMY; WORLD HEALTH ORGANIZATION;

EID: 34047220891     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06537.x     Document Type: Article

References (39)

1. Aul, C., Gattermann, N., Heyll, A., Germing, U., Derigs, G. & Schneider, W. (1992) Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposal for an improved scoring system. Leukemia, 6, 52-59.
2. Aul, C., Giagounidis, A., Germing, U. & Ganser, A. (2002) Evaluating the prognosis of patients with myelodysplastic syndromes. Annals of Hematology, 81, 485-497.
3. Bennett, J.M. (2005) A comparative review of classification systems in myelodysplastic syndromes (MDS). Seminars in Oncology, 32 (Suppl. 5), S3-S10.
4. Bernasconi, P., Alessandrino, E.P., Boni, M., Bonfichi, M., Morra, E., Lazzarino, M., Canpagnoli, C. & Astori, C. (1994) Karyotype in myelodysplastic syndromes: relations to morphology, clinical evolution and survival. American Journal of Hematology, 46, 270-277.
5. Bernasconi, P., Klersy, C., Boni, M., Cavigliano, P.M., Giardini, I., Rocca, B., Zappatore, R., Caresana, M., Quarna, J., Lazzarino, M. & Bernasconi, C. (2005) Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution. Leukemia, 19, 1424-1431.
6. Bowen, D., Culligan, D., Jowitt, S., Kelsey, S., Mufti, G., Oscier, D. & Parker, J. (2003) Guidelines for the diagnosis and therapy of adult myelodysplastic syndrome. British Journal of Haematology, 120, 187-200.
7. Byrd, J., Mrozek, K., Dodge, R.K., Carroll, A.J., Edwards, C.G., Arthur, D.C., Pettinati, M.J., Patil, S.R., Rao, K.W., Watson, M.S., Koduru, P.R., Moore, J.O., Stone, R.M., Mayer, R.J., Feldman, E.J., Davey, F.R., Schiffer, C.A., Larson, R.A. & Bloomfield, C.D. (2002) Cancer and Leukemia Group B (CALGB 8461). Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute leukaemia: results from Cancer and leukaemia Group B. Blood, 100, 4325-4336.
8. Čermàk, J., Beličková, M., Krejčová, H., Michalová, K., Žilovcová, S., Zemanovà, Z., Březinovà, J. & Sieglovà, Z. (2005) The presence of clonal cell subpopulation in peripheral blood and bone marrow of patients with refractory cytopenia with multilineage dysplasia but not in patients with refractory cytopenia may reflect a multistep pathogenesis of myelodysplasia. Leukaemia Research, 29, 371-379.
9. Germing, U., Gattermann, N., Strupp, C., Aivado, M. & Aul, C. (2000a) Validation of the WHO proposal for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leukaemia Research, 24, 983-992.
10. Germing, U., Gattermann, N., Aivado, M., Hildebrandt, B. & Aul, C. (2000b) Two types of acquired idiopathic sideroblastic anaemia (AISA): a time-tested distinction. British Journal of Haematology, 108, 724-728.
11. Germing, U., Hildebrandt, B., Pfeilstöcker, M., Nösslinger, T., Valent, P., Fonatsch, C., Lübbert, M., Haase, D., Steidl, C., Krieger, O., Stauder, R., Giagounidis, A.A.N., Strupp, C., Mueller, T., Haas, R., Gattermann, N. & Aul, C. (2005) Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia, 19, 2223-2231.
12. Giagounidis, A.A.N., Germing, U., Haase, S., Hildebrandt, B., Schlegelberger, B., Schoch, C., Wilkens, L., Heinsch, M., Willems, H., Aivado, M. & Aul, C. (2004) Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia, 18, 113-119.
13. Greenberg, P., Cox, C., Le Beau, M.M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G. & Bennet, J. (1997) International system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, 2079-2088.
14. Howe, B., Porwit-MacDonald, A., Wanat, R., Tehranchi, R. & Hellström-Lindberg, E. (2004) The WHO classification of MDS does make a difference. Blood, 103, 3265-3270.
15. Jaffe, E.S., Harris, N.L., Stein, H. & Vardiman, J.W. (Eds.) (2001) Tumours of Haematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours. IARC Press, Lyon.
16. Kaplan, E. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457-481.
17. Lee, J.-H., Lee, J.-H., Shin, Y.-R., Kim, W.-K., Chi, H.-S., Park, C.-J., Seo, E.-J. & Lee, K.-H. (2003) Application of different prognostic scoring systems and comparison of the FAB and WHO classification in Korean patients with myelodysplastic syndromes. Leukemia, 17, 305-313.
18. Malcovati, L., Della Porta, M.G., Pascutto, C., Invernizzi, R., Boni, M., Travaglino, E., Passamonti, F., Arcaini, L., Maffioli, M., Bernasconi, P., Lazzarino, M. & Cazzola, M. (2005) Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. Journal of Clinical Oncology, 23, 7594-7603.
19. Maserati, E., Aprili, F., Vinante, F., Locatelli, F., Amendola, G., Zatterale, A., Milone, G., Minelli, A., Bernardi, F., Lo Curto, F. & Pasquali, F. (2002) Trisomy 8 in myelodysplasia and acute leukemia is constitutional in 15-20% of cases. Genes Chromosomes and Cancer, 33, 93-97.
20. Mitelman, F. (ed) (1995) ISCN: An International System for Human Cytogenetic Nomenclature. S. Karger, Basel.
21. Morel, P., Hebbar, M., Lai, J.L., Duhamel, A., Preudhomme, C., Wattel, E., Bauters, F. & Fenaux, P. (1993) Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia, 9, 1315-1323.
22. Mufti, G.J., Stevens, J.R., Oscier, D.G., Hamblin, T.J. & Machin, D. (1985) Myelodysplastic syndromes: a scoring system with prognostic significance. British Journal of Haematology, 59, 425-433.
23. Nösslinger, T., Reisner, R., Koller, E., Grüner, H., Tüchler, H., Nowotny, H., Pittermann, E. & Pfeilstöcker, M. (2001) Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution. Blood, 98, 2935-2941.
24. Olney, H.J. & Le Beau, M.M. (2001) The cytogenetics of myelodysplastic syndromes. Best Practice and Research in Clinical Hematology, 14, 479-495.
25. Panani, A.D., Pappa, V., Papageorgiou, S., Stamatelli, F. & Raptis, S.A. (2004) Deletion (11)(q13) as the sole anomaly in myeloid malignancies: four new cases and a short review. Annals of Hematology, 83, 153-155.
26. Parlier, V., van Melle, G., Beris, Ph, Schmidt, P.M., Tobler, A., Haller, E. & Bellomo, M.J. (1995) Prediction of 18-month survival in patients with primary myelodysplastic syndrome. A regression model and scoring system based on the combination of chromosome findings and the Bournemouth score. Cancer Genetics and Cytogenetics, 81, 158-165.
27. Paulsson, K., Säll, T., Fioretos, T., Mitelman, F. & Johansson, B. (2001) The incidence of trisomy 8 as a sole chromosomal aberration in myeloid malignancies varies in relation to gender, age, prior iatrogenic genotoxic exposure, and morphology. Cancer Genetics and Cytogenetics, 130, 160-165.
28. Paulsson, K., Heidenblad, M., Strombeck, B., Staaf, J., Jonsson, G., Borg, Å., Fioretos, T. & Johansson, B. (2006) High-resolution genome-wide array-based comparative genome hybridisation reveals cryptic chromosome changes in AML and MDS cases with trisomy 8 as the sole cytogenetic aberration. Leukemia, 20, 840-846.
29. Pfeilstöcker, M., Reisner, R., Nösslinger, T., Grüner, H., Nowotny, H., Tüchler, H., Schlögl, E., Pittermann, E. & Heinz, R. (1999) Cross-validation of prognostic scores in myelodysplastic syndromes on 386 patients from a single institution confirms the importance of cytogenetics. British Journal of Haematology, 106, 455-463.
30. Pierre, R.V., Catovsky, D., Mufti, G.J., Swansbury, G.J., Mecucci, C., Dewald, G.W., Ruutu, T., den Berghe, H., Rowley, J.D., Mitelman, F., Reeves, B.R., Alimena, G., Garson, O.M., Lawler, S.D. & de la Chapelle, A. (1989) Clinical-cytogenetic correlations in myelodysplasia (Preleukemia). Cancer Genetics and Cytogenetics, 40, 149-161.
31. Ramos, F., Fernandez-Ferrero, S., Suarez, D., Barbon, M., Rodriguez, J.A., Megido, M., Ciudad, J., Lopez, N., del Canizo, C. & Orfao, A. (1999) Myelodysplastic syndrome: a search for minimal diagnostic criteria. Leukaemia Research, 23, 283-290.
32. Rosati, S., Mick, R., Xu, F., Stonys, E., Le Beau, M.M., Larson, R. & Vardiman, J.W. (1996) Refractory Cytopenia with multilineage displasia: further characterization of an "unclassifiable" myelodysplastic syndrome. Leukemia, 10, 20-26.
33. Sanz, G.F., Sanz, M.A., Vallespi, T., del Canizo, M.C., Torrabadella, M., Garcia, S., Irriguible, D. & San Miguel, J.F. (1989) Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood, 74, 395-408.
34. Schemper, M. & Smith, T.L. (1996) A note on quantifying follow-up in studies of failure times. Controlled Clinical Trials, 17, 343-346.
35. Schoch, C., Kohlmann, A., Dugas, M., Kern, W., Hiddemann, W., Schnittinger, S. & Haferlach, T. (2005) Genomic gains and losses influence expression levels of genes located within the affected regions: a study on acute myeloid leukemias with trisomy 8, 11, or 13, monomy 7, or deletion 5q. Leukemia, 19, 1224-1228.
36. Solē, F., Espinet, B., Sanz, G., Cervera, J., Calasanz, M.J., Luño, E., Prieto, F., Granada, I., Hernandez, J.M., Cigudosa, J.C., Diez, J.L., Bureo, E., Marqués, M.L., Arranz, E., Rios, R., Climent, J.A., Vallespi, T., Florensa, L. & Woessner, S. (2000) Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. British Journal of Haematolology, 108, 346-356.
37. Solé, F., Luño, E., Sanzo, C., Espinet, B., Sanz, G.F., Cervera, J., Calasanz, M.J., Cigudosa, J.C., Millà, F., Ribera, J.M., Bureo, E., Martin, M.L., Arranz, E. & Florensa, L. (2005) Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica, 90, 1168-1178.
38. Sperr, W.R., Wimazal, F., Kundi, M., Fonatsch, C., Thalhammer-Scherrer, R., Schernthaner, G.H., Schwarzinger, I., Haas, O.A., Geissler, K., Lechner, K. & Valent, P. (2001) Survival analysis and AML development in patients with de novo myelodysplastic syndromes: comparison of six different prognostic scoring systems. Annals of Hematology, 80, 272-277.
39. Toyama, K., Ohyashiki, K., Yoshida, Y., Abe, T., Asano, S., Hirai, H., Hirashima, K., Hotta, T., Kuramoto, A., Kuriya, S., Miyazaki, T., Kakishita, E., Mizoguchi, H., Okada, M., Shirakawa, S., Takaku, F., Tomonaga, M., Uchino, H., Yasunaga, K. & Nomura, T. (1993) Clinical implications of chromosome abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan. Leukemia, 7, 499-508.